MYC and cancer: Challenges and limitations: Given the well-documented heterogeneity of TECs across varying TME 78, comprehensive clinical validation is required but not limited to facilitate the translation of these preclinical findings to patients: systematically quantify MYC expression levels in TECs from diverse human cancer types; establish robust correlations between MYC expression and endothelial proliferation, inflammatory response signatures, anti-angiogenic treatment outcome, and immunotherapy response profiles.